Pip-Tryptamine
| Clinical data | |
|---|---|
| Other names | 3-(2-Piperidinoethyl)indole; N-Piperidyltryptamine; N,N-Piperidyltryptamine; Piperidinyltryptamine; Piperidinotryptamine; PIT; N,N-Pentamethylenetryptamine |
| Drug class | Serotonin receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C15H20N2 |
| Molar mass | 228.339 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
pip-Tryptamine (pip-T), also known as N,N-pentamethylenetryptamine, N,N-piperidyltryptamine, or 3-(2-piperidinoethyl)indole, is a serotonin receptor modulator and possible serotonergic psychedelic of the tryptamine family. It is the derivative of tryptamine in which the amine has been cyclized into a piperidine ring.
Its affinities (IC50) for serotonin receptors were 600 nM for the serotonin 5-HT1A receptor, 760 nM for the serotonin 5-HT2A receptor, and 1,250 nM for the serotonin 5-HT2B receptor, whereas other serotonin receptors were not reported. The affinity of pip-T for the serotonin 5-HT2A receptor was about 10-fold lower than that of dimethyltryptamine (DMT) and was about 7-fold lower than that of pyr-tryptamine (pyr-T; N,N-pyrrolidinyltryptamine).
The drug produces hypolocomotion in rodents. In addition, it induces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. This was blocked by the serotonin 5-HT2A receptor antagonist ketanserin. Hence, the drug may have hallucinogenic effects in humans. Conversely, pip-T did not produce conditioned place preference (CPP) and was not self-administered, suggesting that it lacks reinforcing properties and misuse potential, similarly to most other tryptamines.
Pip-T was first described in the scientific literature by 1959 and was more thoroughly characterized in 1990 and 2020.